EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer

Veda B Hacholli iD, Shubha M R, Prabhanajan B H, Lavanya M, Pramod S, Abhishek Kumar, Łukasz Szeleszczuk iD, Marcin Gackowski iD

Molecules · 23.10.2025 · 30 (21) · 4167

DOI: 10.3390/molecules30214167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 23.10.2025. Verfasst von Veda B Hacholli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nitte College of Pharmaceutical Sciences, Nitte (Deemed to be University), Bengaluru 560…. Hauptthemen laut MEDLINE: Coumarins, Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coumarin derivatives constitute a versatile small-molecule chemotype with broad anticancer potential. This narrative review synthesizes recent in vitro and in vivo evidence on coumarin-based scaffolds, emphasizing breast cancer and covering lung, prostate, and colorectal models. We summarize major mechanisms of action—including induction of apoptosis (caspase activation and BAX/BCL-2 balance), modulation of PI3K/Akt/mTOR signaling, inhibition of angiogenesis (VEGFR-2), interference with estrogen biosynthesis (aromatase/ER axis), chaperone targeting (Hsp90), and attenuation of multidrug resistance (efflux pumps/autophagy)—and highlight representative chemotypes (e.g., benzimidazole, triazole, furocoumarins, topoisomerase- and CDK-oriented hybrids). Where available, we contrast potency and selectivity across models (e.g., MCF-7 vs. MDA-MB-231; A549; PC-3; colon lines) and discuss structure–activity trends linking substituent patterns (heteroaryl linkers, judicious halogenation, polar handles) to pathway engagement. We also delineate translational gaps limiting clinical progress—selectivity versus non-malignant cells, incomplete pharmacokinetic and safety characterization, and limited validation beyond xenografts. Finally, we outline priorities for preclinical optimization: biology-aligned target selection with biomarkers, resistance-aware combinations (e.g., PI3K/mTOR ± autophagy modulation; MDR mitigation), and early integration of ADME/tox and PK/PD to confirm on-target exposure. Collectively, the evidence supports coumarins as adaptable, multi-target anticancer leads, particularly promising in hormone-dependent breast cancer while remaining relevant to other tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoumarinsAntineoplastic AgentsBreast NeoplasmsHumansAnimalsFemaleSignal TransductionApoptosisStructure-Activity Relationship

Stichwörter der Autor:innen

PI3K/Akt/mTORVEGFR-2apoptosisaromatasebreast cancercoumarinfurocoumarinmultidrug resistance

Substanzen

CoumarinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nitte College of Pharmaceutical Sciences, Nitte (Deemed to be University), Bengaluru 560064, KA, India.
  • ITAAN PHARMA PVT. Ltd., Plot No S-9, Genome Valley Phase III, Biotech Park, Karkapatla 5022812, TG, India.
  • Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Mangalore 560064, KA, India.
  • Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Street, PL-02093 Warsaw, Poland.
  • Department of Toxicology and Bromatology, Faculty of Pharmacy, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, A. Jurasza 2 Street, PL-85089 Bydgoszcz, Poland.

ORCID-Profile: Veda B Hacholli, Łukasz Szeleszczuk, Marcin Gackowski

Zitieren

APA

Hacholli, V. B., R, S. M., H, P. B., M, L., S, P., Kumar, A., Szeleszczuk, Ł., & Gackowski, M. (2025). Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer. Molecules, 30(21), 4167. https://doi.org/10.3390/molecules30214167

Vancouver

Hacholli VB, R SM, H PB, M L, S P, Kumar A, et al. Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer. Molecules. 2025;30(21):4167. doi:10.3390/molecules30214167

BibTeX
@article{Hacholli2025,
  author = {Hacholli, Veda B and R, Shubha M and H, Prabhanajan B and M, Lavanya and S, Pramod and Kumar, Abhishek and Szeleszczuk, Łukasz and Gackowski, Marcin},
  title = {Coumarin Derivatives as Anticancer Agents: Mechanistic Landscape with an Emphasis on Breast Cancer},
  journal = {Molecules},
  year = {2025},
  volume = {30},
  number = {21},
  pages = {4167},
  doi = {10.3390/molecules30214167}
}
Kostenlos starten →